Latest Breaking News On - ஜான்சன் பயோடெக் இன்க் - Page 10 : comparemela.com

Hits: 233 DARZALEX FASPRO® is now the first and only subcutaneous anti-CD38 monoclonal antibody approved in combination with pomalidomide and dexamethasone HORSHAM, PA, USA I July 12, 2021 I The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. The approval follows the regulatory submission to the FDA in November 2020 and marks the sixth indication for DARZALEX

United statesCraig tendlerMeletiosa dimopoulosGlobal medical affairsSlate developmentJanssen biotech incDrug administrationJanssen research developmentJanssen pharmaceutical companies of johnsonAmerican society of hematologyCompanies of johnsonKapodistrian university of athens school medicineDepartment of clinical therapeuticsAmerican cancer societyMultiple myeloma after firstSubsequent relapse